Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 9Recruiting 4Terminated 3Active not recruiting 3Unknown 2Withdrawn 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Melanoma 17Carcinoma, Non-Small-Cell Lung 13Squamous Cell Carcinoma of Head and Neck 7Lung Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 4Head and Neck Neoplasms 4Neoplasms 3Multiple Myeloma 3Lymphoma 3Leukemia, Myeloid, Acute 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Sarcoma 2Myelodysplastic Syndromes 2Lymphoma, B-Cell 2Hematologic Neoplasms 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Resectable Non-Small Cell Lung Cancer 1

Interventions

trametinib 2olaparib 1glembatumumab vedotin 1durvalumab 1cediranib 1Vorinostat 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1CR011-vcMMAE 1Biopsy, Fine-Needle 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Uveal Melanoma × Nivolumab × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡